2026-08-12T15:21:55-05:00 2026-03-31 390859910 BAKER TILLY ADVISORY GROUP LP 6320 CANOGA AVENUE 17TH FLOOR WOODLAND HILLS CA 91367 990 2025-04-01 954002032 THE ALFRED E MANN FOUNDATION FOR SCIENTIFIC RESEARCH ALFR 6617026700 25134 RYE CANYON LOOP SANTA CLARITA CA 91355 ROBERT GREENBERG CEO 6617026700 2026-08-11 1 QI WEN LIANG P01270238 8185771900 2026-08-11 2025 2025-03-06 01:10:19Z HUMANNITY MEDTEC ROBERT GREENBERG 25134 RYE CANYON LOOP SANTA CLARITA CA 91355 298778593 0 X WWW.HUMANNITYMEDTEC.ORG X 1985 CA CONDUCT MEDICAL AND SCIENTIFIC RESEARCH 5 4 147 4 125 0 378 46500 420079 10105218 14822058 21531091 2901867 226204806 18144382 257887615 10000 10000 0 0 21161843 44932488 0 0 0 20604681 27740023 41776524 72682511 -23632142 185205104 353361768 567896814 6385007 12714596 346976761 555182218 X THE ALFRED E. MANN FOUNDATION FOR SCIENTIFIC RESEARCH (AMF) DBA HUMANNITY MEDTEC (HMT) IS A MEDICAL RESEARCH ORGANIZATION DEDICATED TO DEVELOPING AND COMMERCIALIZING INNOVATIVE SOLUTIONS FOR SIGNIFICANT UNMET MEDICAL CONDITIONS. 0 0 36717119 0 226308037 NEW PROJECT DEVELOPMENTTHIS PROGRAM COVERS (A) THE MONITORING AND EVALUATION OF SEVERAL EARLY STAGE ADVANCED RESEARCH AND DEVELOPMENT EFFORTS UNDERWAY THAT ARE DIRECTED AT DEVELOPING - INNOVATIVE TECHNOLOGIES, PROJECT IDEAS AND CONCEPTS BEFORE THEY PROGRESS TO THE STATUS OF FULL-FLEDGED DEVELOPMENT PROGRAMS, AND (B) ONGOING EFFORTS RELATED TO THE ADVANCEMENT OF COMMERCIAL DEVELOPMENT AND PROTECTION OF INTELLECTUAL PROPERTY OF THESE PROJECTS ACROSS THE DEVELOPMENT LIFECYCLE. THE TEAM COMPRISES THE FULL RANGE OF EXPERTISE AVAILABLE AT AMF/HMT, INCLUDING EXECUTIVE MANAGEMENT, RESEARCH SCIENTISTS AND ENGINEERS, LEGAL AND INTELLECTUAL PROPERTY EXPERTS, BUSINESS DEVELOPMENT STRATEGISTS AND ANALYSTS.EXPENSES MAY INCLUDE ONGOING PARTICIPATION IN THE DEVELOPMENT EFFORT, INCLUDING RESEARCH AND DEVELOPMENT SUPPORT, COLLABORATION MANAGEMENT, CONFERENCE AND PROFESSIONAL SOCIETY MEETING ATTENDANCE, SERVICE IN MANAGEMENT OR ON THE BOARD OF DIRECTORS OF SPINOUT ENTITIES, PATENT PROSECUTION AND THE PROSECUTION OF INFRINGEMENT ACTIONS TO PROTECT THE VALUE OF THE INTELLECTUAL PROPERTY WE CREATE. IN ADDITION TO PAYROLL EXPENSES AND DIRECT EXPENSES PAID TO OUTSIDE VENDORS FOR GOODS AND SERVICES RELATED TO PROJECTS, EXPENSES IN THIS PROGRAM MAY INCLUDE TRAVEL EXPENSES, PATENT PROSECUTION EXPENSES AND FEES, LEGAL FEES FOR EXPENSES TO CREATE, PRESERVE AND PROTECT INTELLECTUAL PROPERTY FROM INFRINGEMENT AND REMEDY PAST INFRINGEMENT, AND INCENTIVE AND OTHER COMPENSATION PAYMENTS TO EMPLOYEES AND OTHERS RELATED TO THESE PROGRAMS AND ACTIONS. IN SOME CASES, CERTAIN OF THESE EXPENDITURES MIGHT BE INCURRED LONG AFTER THE PROGRAMS HAVE BEEN LAUNCHED INTO SPINOUT COMPANIES OR LICENSED TO THIRD PARTIES.REVENUES ASSOCIATED WITH THESE PROJECTS (SOME OF WHICH MAY ACCRUE LONG AFTER THE PROJECT AND ANY RELATED PROGRAM HAVE BEEN OUTLICENSED OR LAUNCHED INTO A SPINOUT COMPANY) MAY INCLUDE: RECOVERIES OF JUDGMENTS OR SETTLEMENTS FROM PATENT INFRINGEMENT AND LICENSING MATTERS, ROYALTIES ON LICENSED PRODUCT SALES, MILESTONE PAYMENTS, ONGOING CONTRACT R&D SERVICES PROVIDED TO PARTNERS, LICENSEES AND SPINOUT COMPANIES, INTEREST, AND PROCEEDS FROM LIQUIDITY EVENTS (E.G., INITIAL PUBLIC OFFERINGS, ACQUISITIONS) INVOLVING RETAINED EQUITY INTERESTS IN PROJECTS THAT HAVE BEEN SPUN OUT AS STARTUP COMPANIES.STATUS:DESIGN AND DEVELOPMENT ACTIVITIES ARE UNDERWAY FOR A NEW BIOELECTRONIC PROGRAM BASED ON EXISTING BUSINESS CASE ANALYSES. THESE ACTIVITIES INCLUDE GENERATION OF INITIAL SYSTEM REQUIREMENTS, ASSEMBLY OF A TEAM OF KEY OPINION LEADERS WITH DOMAIN EXPERTISE, AND THE INITIATION OF SOME FUNDAMENTAL APPLIED RESEARCH IN THE AREA OF NOVEL STIMULATION TECHNIQUES, INCLUDING COMPLETION OF PRE-CLINICAL TESTING. ADDITIONALLY, THE BUSINESS DEVELOPMENT TEAM, ALONG WITH EXECUTIVE MANAGEMENT AND OTHER STAFF, PERFORMED PRELIMINARY DUE DILIGENCE ON A NUMBER OF PROJECTS. 16985902 10000 0 NEUROMODULATION SYSTEMADVANCED IMPLANTABLE NEUROMODULATION SYSTEM DEVELOPMENT:THIS PROGRAM COVERS (A) THE MONITORING AND EVALUATION OF SEVERAL EARLY-STAGE ADVANCED RESEARCH AND DEVELOPMENT EFFORTS UNDERWAY THAT ARE DIRECTED AT DEVELOPING INNOVATIVE TECHNOLOGIES, PROJECT IDEAS AND CONCEPTS BEFORE THEY PROGRESS TO THE STATUS OF FULL-FLEDGED DEVELOPMENT PROGRAMS, AND (B) ONGOING EFFORTS RELATED TO THE ADVANCEMENT OF COMMERCIAL READINESS AND PROTECTION OF RELATED INTELLECTUAL PROPERTY ACROSS THE DEVELOPMENT LIFECYCLE. THE TEAM COMPRISES THE FULL RANGE OF EXPERTISE AVAILABLE AT AMF/HMT, INCLUDING EXECUTIVE MANAGEMENT, RESEARCH SCIENTISTS AND ENGINEERS, LEGAL AND INTELLECTUAL PROPERTY EXPERTS, BUSINESS DEVELOPMENT STRATEGISTS AND ANALYSTS.STATUS RESEARCH AND DEVELOPMENT ACTIVITIES ARE UNDERWAY TO ENHANCE THE CAPABILITIES OF A NEUROMODULATION SYSTEM, COMPRISED OF ADVANCED TECHNOLOGIES AND SYSTEM SOLUTIONS IN SUPPORT OF NEW BUSINESS DEVELOPMENT STRATEGIES. 10033758 0 0 IMPLANTABLE NEUROMODULATION PROJECT #1 TO TREAT CHRONIC DISEASE -THE AIM OF THE AMF/HMT PROGRAM IS TO DEVELOP A NEUROSTIMULATION SYSTEM THAT WILL IMPROVE MEDICAL OUTCOMES AT A LOWER COST AND/OR HIGHER PATIENT SATISFACTION THAN CURRENTLY AVAILABLE TREATMENT OPTIONS. SUCH A SYSTEM WILL CONSIST OF A FULLY IMPLANTABLE NEURAL STIMULATOR FOR SEAMLESS OPERATION AND REQUIRING MINIMAL INTERACTION FROM A PATIENT, WITH THE GOAL OF OFFERING A HIGHER LEVEL OF PATIENT SATISFACTION, ADOPTION, AND COMPLIANCE.STATUS:FINAL DESIGN VERIFICATION TESTING ACTIVITIES OF THE IMPLANTABLE DEVICE AND EXTERNALS ARE COMPLETED. A FIRST-IN-HUMAN STUDY TO ASSESS THE SYSTEM DESIGN AND THERAPY IS ONGOING. 2466959 0 0 IMPLANTABLE NEUROMODULATION PROJECT #2: A-$279,169.06 & B-$2,187,790.66TO TREAT A RANGE OF NEUROLOGICAL CONDITIONS. THE SYSTEM WILL CONSIST OF AN IMPLANTABLE NEURAL STIMULATOR AND EXTERNALS DESIGNED TO MAXIMIZE THERAPY OUTCOMES AND PATIENT SATISFACTION WHILE MINIMIZING SYSTEM COSTS.STATUS:PLANNING, DESIGN, AND DEVELOPMENT OF THE FIRST IN-HUMAN IMPLANT AND EXTERNALS IS UNDERWAY; FEASIBILITY PLANNING AND INITIATIVES INCLUDE PRE-CLINICAL STUDIES AND COMPUTATIONAL MODELING OF TARGETED NEURAL STRUCTURES. 5451 10001987 IMPLANTABLE DRUG PUMP (IDP)THE IDP IS A SOPHISTICATED, HIGHLY PROGRAMMABLE DRUG INFUSION DEVICE THAT IS IMPLANTED IN THE BODY AND REFILLED VIA A HYPODERMIC NEEDLE THROUGH THE SKIN. INFUSION RATES AND SCHEDULES MAY BE PROGRAMMED, AND VIA VARIOUS FORMS OF CATHETERS, DRUGS CAN BE DELIVERED INTRATHECALLY TO THE SPINAL COLUMN, INTO THE ABDOMEN, INTO THE BRAIN, OR INTRAVENOUSLY. STATUS: AMF/HMT HAS SOLD THE IDP TECHNOLOGY TO A STRATEGIC PARTNER THAT IS AN INTERNATIONAL MEDICAL DEVICE COMPANY. AMF/HMT CONTINUES TO SUPPORT THE STRATEGIC PARTNER AS IT CONDUCTS CLINICAL TRIALS AND READIES IT FOR COMMERCIALIZATION FOR THE BENEFIT OF PATIENTS. 2472410 0 10001987 66209189 1 1 0 0 0 0 0 0 0 0 1 1 0 0 1 1 1 0 0 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 59 0 1 147 1 0 0 0 0 0 0 0 0 0 0 1 0 X 5 4 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 1 1 CA X FARAH BOROOMAND 6617026731 25134 RYE CANYON LOOP SANTA CLARITA CA 91355 ROBERT GREENBERG CEO/PRESIDENT/CHAIR OF THE BOARD 40.00 X X 1702823 0 128489 DAVID GILL BOARD MEMBER 1.50 X 0 0 0 HEATHER PAGE BOARD MEMBER 1.25 X 0 0 0 KEN WEATHERWAX BOARD MEMBER 1.25 X 0 0 0 RICHARD WAUGH BOARD MEMBER 1.50 X 0 0 0 FARAH BOROOMAND CHIEF FINANCIAL OFFICER/TREASURER 40.00 X 674156 0 65659 COREY DISHMON CHIEF BUSINESS AND LEGAL OFFICER 40.00 X 591154 0 39697 PHILIP LEE SECRETARY/ ASSISTANT GENERAL COUNSEL 40.00 X 228422 0 30806 JOHN RIVERA VICE PRESIDENT, PRODUCT DEVELOPMENT 41.00 X 371763 0 50464 CEDRIC NAVARRO VP, QUALITY ASSURANCE, REG. AFFAIRS, OPERATIONS 40.00 X 335094 0 50020 NEIL TALBOT VP, RESEARCH AND TECHNOLOGY 40.00 X 475370 0 43404 BRIAN SHELTON SENIOR DIR, SOFTWARE ENGINEERING 40.00 X 387389 0 25252 SHAWN LEWIS VICE PRESIDENT, HUMAN RESOURCES 40.00 X 353262 0 12647 BRIAN MECH VICE PRESIDENT, STRATEGY 40.00 X 330942 0 11366 JOSEPH CALDERON SENIOR DIR, MECHANICAL ENGINEER 43.00 X 327174 0 51008 5777549 0 508812 78 0 1 0 MORGAN LEWIS & BOCKIUS LLP 1701 MARKET STREET PHILADELPHIA PA 19103 LEGAL SERVICES 10911980 JAMS INC PO BOX 845402 LOS ANGELES CA 90084 PROFESSIONAL FEES 1000815 JS HELD LLC 50 JERICHO QUADRANGLE SUITE 117 JERICHO NY 11753 PROFESSIONAL FEES 459772 WOMBLE BOND DICKINSON (US) LLP ONE WEST FOURTH STREET WINSTON SALEM NC 27101 LEGAL SERVICES (PATENTS) 395519 SYNERGOUS LLC (DBA IC ENABLE) 800 E CAMPBELL RD SUITE101 RICHARDSON TX 75081 PROFESSIONAL FEES 341303 14 46500 46500 OTHER INCOME 541700 10000000 10000000 NEW PROJECTS 541700 103231 103231 IMPLANTABLE DRUG PUMP (IDP) 541700 1987 1987 10105218 10239040 125 10238915 1204806 1204806 52183029 40865205 25773 11317824 -25773 11292051 11292051 LEGAL SETTLEMENT PROCEEDS 900099 225000000 225000000 225000000 257887615 236310024 125 21530966 10000 10000 6705576 4762570 1943006 34070288 32937638 1132650 469175 423791 45384 2089249 1929664 159585 1598200 1382993 215207 11511097 11319061 192036 188648 188648 1210844 1210844 4228559 3809452 419107 4683522 4568761 114761 825247 808729 16518 1825551 1628063 197488 587919 516460 71459 169526 124148 45378 1504344 1417164 87180 239659 212820 26839 RECRUITING EXP & RELOCA 381345 381345 EMPLOYEE MORALE 304383 293990 10393 EMPLOYEE TRAINING 53389 39364 14025 MEALS 21637 20168 1469 4353 4353 72682511 66209189 6473322 0 602819 1476562 88774317 273445170 296888 552196 14051772 8720196 4469669 5331576 194030607 229458245 61869909 54671145 1062425 1868613 2255134 1093307 353361768 567896814 4289806 11209057 2095201 1505539 6385007 12714596 X 346976761 555182218 346976761 555182218 353361768 567896814 185205104 23000353 0 X 0 1 X 1 0 X UCLA FOUNDATION LOS ANGELES CA RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 1567297 1259694 307603 10514069 6001344 4512725 1970406 1459158 511248 5331576 HEDGE FUNDS INTERNATIONAL 51167049 F LIMITED PARTNERSHIPS 2458 F OTHER INVESTMENTS 3501638 F 54671145 OPERATING LEASE LIABILITIES 1505539 1505539 X 280887968 23000353 23000353 257887615 0 257887615 72682511 0 72682511 0 72682511 PART X, LINE 2: THE ALFRED E. MANN FOUNDATION FOR SCIENTIFIC RESEARCH IS EXEMPT FROM FEDERAL INCOME AND CALIFORNIA FRANCHISE TAXES UNDER SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE (THE "CODE") AND THE CORRESPONDING CALIFORNIA PROVISIONS. THE ALFRED E. MANN FOUNDATION FOR SCIENTIFIC RESEARCH HAD NO SIGNIFICANT UNRELATED BUSINESS INCOME TAX DURING THE YEAR ENDED MARCH 31, 2026. ACCORDINGLY, NO TAX PROVISION FOR UNRELATED BUSINESS INCOME HAS BEEN MADE IN THE ACCOMPANYING FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2025 AND 2026. AMF/HMT, UNDER THE PROVISIONS OF ASC 740, INCOME TAXES, HAD NO UNCERTAIN TAX POSITIONS REQUIRING ACCRUAL AS OF MARCH 31, 2025, AND 2026. CENTRAL AMERICA AND THE CARIBBEAN 0 0 INVESTMENTS 31729888 NORTH AMERICA 0 0 INVESTMENTS 2458 SOUTH ASIA 0 0 PROGRAM SERVICES R&D CONSULTING 364693 EUROPE (INCLUDING ICELAND & GREENLAND) 0 0 PROGRAM SERVICES R&D CONSULTING 381217 EAST ASIA AND THE PACIFIC 0 0 PROGRAM SERVICES R&D CONSULTING 387868 NORTH AMERICA 0 0 PROGRAM SERVICES R&D CONSULTING 364990 RUSSIA AND NEIGHBORING STATES 0 0 PROGRAM SERVICES R&D CONSULTING AND INSURANCE 64124 0 0 0 0 0 0 33295238 0 33295238 1 0 1 1 1 0 PART I, LINE 3: THE ACCRUAL METHOD OF ACCOUNTING IS USED FOR BOTH AMOUNTS REPORTED AS INVESTMENTS AND EXPENDITURES. 1 X X X 0 0 0 1 0 0 0 1 0 ROBERT GREENBERG CEO/PRESIDENT/CHAIR OF THE BOARD 612673 0 1090150 0 0 0 10350 0 118139 0 1831312 0 0 0 FARAH BOROOMAND CHIEF FINANCIAL OFFICER/TREASURER 341134 0 333022 0 0 0 10500 0 55159 0 739815 0 0 0 COREY DISHMON CHIEF BUSINESS AND LEGAL OFFICER 356004 0 235150 0 0 0 10245 0 29452 0 630851 0 0 0 NEIL TALBOT VP, RESEARCH AND TECHNOLOGY 268720 0 206650 0 0 0 8704 0 34700 0 518774 0 0 0 JOHN RIVERA VICE PRESIDENT, PRODUCT DEVELOPMENT 311613 0 60150 0 0 0 9845 0 40619 0 422227 0 0 0 BRIAN SHELTON SENIOR DIR, SOFTWARE ENGINEERING 212022 0 175367 0 0 0 7440 0 17812 0 412641 0 0 0 CEDRIC NAVARRO VP, QUALITY ASSURANCE, REG. AFFAIRS, 283944 0 51150 0 0 0 7021 0 42999 0 385114 0 0 0 JOSEPH CALDERON SENIOR DIR, MECHANICAL ENGINEER 195736 0 131438 0 0 0 9734 0 41274 0 378182 0 0 0 SHAWN LEWIS VICE PRESIDENT, HUMAN RESOURCES 302112 0 51150 0 0 0 10500 0 2147 0 365909 0 0 0 BRIAN MECH VICE PRESIDENT, STRATEGY 291242 0 39700 0 0 0 9326 0 2040 0 342308 0 0 0 PHILIP LEE SECRETARY/ ASSISTANT GENERAL COUNSEL 199172 0 29250 0 0 0 5940 0 24866 0 259228 0 0 0 PART I, LINE 5 AWARDS WERE PAID THIS YEAR UNDER INCENTIVE COMPENSATION PLANS SPONSORED BY AMF/HMT. THE PURPOSE OF THESE INCENTIVE PLANS IS TO ENHANCE THE ABILITY OF AMF/HMT TO ATTRACT AND RETAIN HIGHLY QUALIFIED EMPLOYEES BY PROVIDING THEM WITH CASH INCENTIVE COMPENSATION OPPORTUNITIES RELATED TO AMF/HMT'S PROGRAMS AND RESEARCH EFFORTS. TO THE EXTENT THE PLANS PROVIDE FOR A DEFERRAL OF COMPENSATION, THE PLANS ARE INTENDED TO BE INELIGIBLE DEFERRED COMPENSATION PLANS WITHIN THE MEANING OF SECTION 457(F) OF THE CODE. EMPLOYEES DESIGNATED TO PARTICIPATE IN THE INCENTIVE PLANS RECEIVE AWARDS PURSUANT INDIVIDUAL AWARD AGREEMENTS UNDER EACH PLAN. PLAN AWARDS PROVIDE CASH INCENTIVE COMPENSATION AND ARE INTENDED TO SERVE AS A GENERAL EMPLOYEE RETENTION TOOL, AS WELL AS A REWARD FOR KEY PARTICIPANTS IN THE UNDERLYING PROGRAM OR RESEARCH EFFORT THAT IS THE SUBJECT OF SUCH PLAN. UPON ACTUAL RECEIPT BY AMF/HMT OF PROCEEDS RELATED TO THE SALE OR LICENSING OF PARTICULAR ASSETS DEVELOPED BY AMF/HMT IN SUPPORT OF ITS MISSION (AND AFTER DEDUCTING CERTAIN AMOUNTS DESIGNED TO REIMBURSE AMF/HMT FOR ITS COSTS OF THE UNDERLYING ASSET), AN AWARD POOL IS CREATED AND AWARD RECIPIENTS ARE PAID A PERCENTAGE OF THE NET PROCEEDS RECEIVED BY AMF/HMT. TYPICALLY, THE TOTAL AWARDS TO ALL RECIPIENTS IN ANY PLAN DO NOT EXCEED 15.00% OF THE AMOUNT OF NET PROCEEDS REALIZED BY AMF/HMT. NO AMOUNTS ARE PAYABLE UNLESS AND UNTIL AMF/HMT HAS ACTUALLY RECEIVED THE APPLICABLE PROCEEDS. THE AWARDS ARE SUBJECT TO SEVERAL CONDITIONS DESIGNED TO PROVIDE A SUBSTANTIAL RISK OF FORFEITURE TO THE AWARD RECIPIENT. CERTAIN RESTRICTIONS SUCH AS CAPS SET FORTH IN EACH DISQUALIFIED PERSON'S AWARD AGREEMENT PLACE LIMITATIONS ON AWARD AMOUNTS. THE PLANS AND AWARDS WERE APPROVED BY THE BOARD OF DIRECTORS AFTER REVIEWING DETAILED COMPENSATION ANALYSIS INFORMATION PREPARED BY AN INDEPENDENT, NATIONAL EXECUTIVE COMPENSATION FIRM AND RECEIVING OUTSIDE LEGAL ADVICE, BOTH RELATING TO THE REASONABLENESS OF THE AWARD COMPENSATION. THE PLANS REQUIRE THAT THIS COMPENSATION ANALYSIS BE UPDATED AT LEAST EVERY TWO YEARS. PART I, LINE 7 BONUSES ARE PAID PURSUANT TO: #1, "THE ALFRED E. MANN FOUNDATION FOR SCIENTIFIC RESEARCH ANNUAL INCENTIVE PLAN AND #2, "THE ALFRED E. MANN FOUNDATION FOR SCIENTIFIC RESEARCH KEY CONTRIBUTOR AWARD PROGRAM". BOTH PLANS ARE RENEWED AND APPROVED EACH YEAR BY THE BOARD OF DIRECTORS. "THE ALFRED E. MANN FOUNDATION FOR SCIENTIFIC RESEARCH ANNUAL INCENTIVE PLAN" IS BASED ON THE ACHIEVEMENT OF PERSONAL AND CORPORATE GOALS, AMONG OTHER CONSIDERATIONS, WHILE "THE ALFRED E. MANN FOUNDATION FOR SCIENTIFIC RESEARCH KEY CONTRIBUTOR AWARD PROGRAM" IS DESIGNED TO PROVIDE FOR PERFORMANCE AND RETENTION INCENTIVES BASED ON INDIVIDUAL AND FOUNDATION-WIDE PERFORMANCE TO ELIGIBLE EMPLOYEES OF AMF/HMT. FORM 990, PART VI, SECTION B, LINE 11B A DRAFT OF THE 990 WILL BE PRESENTED BY MANAGEMENT TO THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS FOR THEIR REVIEW AND DISCUSSION. A FULL COPY OF THE FORM WILL BE PROVIDED TO ALL VOTING MEMBERS PRIOR TO FILING WITH THE IRS. FORM 990, PART VI, SECTION B, LINE 12C CONFLICT OF INTEREST DISCLOSURES ARE UPDATED ANNUALLY AND POTENTIAL CONFLICTS ARE REVIEWED PRIOR TO PARTICIPATING IN TRANSACTIONS. IF A CONFLICT EXISTS, THE PERSON WITH A CONFLICT DOES NOT VOTE. FORM 990, PART VI, SECTION B, LINE 15 THE BOARD OF DIRECTORS REVIEWS AND APPROVES THE COMPENSATION OF THE CEO AND HIS DIRECT REPORTS INCLUDING THE CFO. IT ALSO REVIEWS AND APPROVES ANNUAL ADJUSTMENTS TO COMPENSATION OF OTHER EMPLOYEES IN THE AGGREGATE. ADJUSTMENTS FOR OTHER EMPLOYEES BELOW THE CEO AND HIS DIRECT REPORTS ARE HANDLED BY THE CEO AND THE HEAD OF HUMAN RESOURCES AFTER REFERENCING MARKET COMPARISONS COMPRISED OF SALARY SURVEYS FOR SIMILAR POSITIONS AND EXPERIENCE. THE BOARD OF DIRECTORS APPROVED COMPENSATION FOR THE CEO AND HIS DIRECT REPORTS INCLUDING THE CFO ON 03/12/2026. THIS REVIEW AND APPROVAL PROCESS WAS DOCUMENTED CONTEMPORANEOUSLY AND INCORPORATED DETAILED COMPARABILITY DATA AND ANALYSIS FROM AN INDEPENDENT NATIONAL EXECUTIVE COMPENSATION ANALYSIS FIRM. FORM 990, PART VI, SECTION C, LINE 19 MEMBERS OF THE PUBLIC OR INTERESTED PARTIES MAY REQUEST TO REVIEW OR RECEIVE A COPY OF THE GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS BY PHONE OR MAIL.